<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39415258</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7517</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Harm reduction journal</Title><ISOAbbreviation>Harm Reduct J</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccination intention among people who use drugs in France in 2021: results from the international community-based research program EPIC.</ArticleTitle><Pagination><StartPage>184</StartPage><MedlinePgn>184</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">184</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12954-024-01096-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">COVID-19 vaccination is crucial to reduce the incidence of severe forms of the disease in the population. However, people who use drugs (PWUD) face structural and individual barriers to vaccination, and little is known about vaccination intention and factors associated with that intention among PWUD. This study aimed to estimate vaccination intention in PWUD and associated factors in the early stage of vaccination campaigns.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted cross-sectional study in France among PWUD, as part of the international EPIC program, a community-based research study coordinated by Coalition PLUS. It included 166 unvaccinated PWUD attending harm reduction centers. A questionnaire collected data on sociodemographic characteristics, COVID-19 related difficulties, and mental health, among other things. Multivariate logistic regression was used to identify factors associated with low vaccination intention.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Only 19% of participants reported strong intention to get vaccinated against COVID-19. Factors independently associated with low vaccination intention were younger age (aOR = 0.90, 95%CI = 0.85-0.95), lower education level (aOR = 2.67, 95% CI = 0.95-7.55), and unstable housing (aOR = 6.44, 95% CI = 1.59-40.34). The most-cited reasons for low intention were mistrust in COVID-19 vaccines (66.1%), fear of side effects (48.7%), and non-belief in vaccinations in general (25.2%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study highlights the need for targeted COVID-19 information and interventions to increase vaccine uptake in PWUD, especially those living in precarity. Community-based interventions and targeted government assistance could play a crucial role in addressing vaccine hesitancy in this population, not only for COVID-19 but for future epidemics.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacoux</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Aides, Pantin, France. lacoux.cynthia@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Community-Based Research Laboratory, Coalition PLUS, Pantin, France. lacoux.cynthia@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villes</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Community-Based Research Laboratory, Coalition PLUS, Pantin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riegel</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Community-Based Research Laboratory, Coalition PLUS, Pantin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coulmain</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Aides, Pantin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorente</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Community-Based Research Laboratory, Coalition PLUS, Pantin, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Estudis Epidemiològics Sobre Les Infeccions de Transmissió Sexual i Sida de Catalunya (CEEISCAT), Agència de Salut Pública de Catalunya, Badalona (Barcelona), 08916, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derras</LastName><ForeName>S Eddine</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Aides, Pantin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>D Rojas</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Community-Based Research Laboratory, Coalition PLUS, Pantin, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale, Aix Marseille Univ, Inserm, IRD, ISSPAM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roux</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>SESSTIM, Sciences Economiques &amp; Sociales de la Santé &amp; Traitement de l'Information Médicale, Aix Marseille Univ, Inserm, IRD, ISSPAM, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delabre</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Community-Based Research Laboratory, Coalition PLUS, Pantin, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michels</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Aides, Pantin, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Community-Based Research Laboratory, Coalition PLUS, Pantin, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Harm Reduct J</MedlineTA><NlmUniqueID>101153624</NlmUniqueID><ISSNLinking>1477-7517</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033182" MajorTopicYN="Y">Intention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055030" MajorTopicYN="N">Drug Users</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000088823" MajorTopicYN="N">Vaccination Hesitancy</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Community-based research</Keyword><Keyword MajorTopicYN="N">People who use drugs</Keyword><Keyword MajorTopicYN="N">Vaccination intention</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39415258</ArticleId><ArticleId IdType="pmc">PMC11481597</ArticleId><ArticleId IdType="doi">10.1186/s12954-024-01096-6</ArticleId><ArticleId IdType="pii">10.1186/s12954-024-01096-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lechner-Scott J, Levy M, Hawkes C, Yeh A, Giovannoni G. Long COVID or post COVID-19 syndrome. Mult Scler Relat Disord oct. 2021;55:103268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8447548</ArticleId><ArticleId IdType="pubmed">34601388</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy févr. 2021;76(2):428–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 30 déc 2020;NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med [Internet]. [cité 11 janv 2023]; Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220996/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 10 déc 2020;NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadet-Taïrou A, Lermenier-Jeannet A, Gautier S. Profils et pratiques des usagers de drogues rencontrés dans les CAARUD en 2015 [Internet]. Observatoire français des drogues et des toxicomanies; 2015 [cité 5 juin 2023]. Disponible sur: https://www.ofdt.fr/publications/collections/etudes-et-recherches/2018/profils-et-pratiques-des-usagers-de-drogues-rencontres-dans-les-caarud-en-2015/</Citation></Reference><Reference><Citation>Palle C. Les personnes accueillies dans les CSAPA - Situation en 2014 et évolution depuis 2007 [Internet]. Observatoire français des drogues et des toxicomanies; 2016 juin [cité 18 juill 2023]. (Tendances). Report No.: 110. Disponible sur: https://www.ofdt.fr/publications/collections/tendances/les-personnes-accueillies-dans-les-csapa-situation-en-2014-et-evolution-depuis-2007-tendances-110-juin-2016/</Citation></Reference><Reference><Citation>Nelson PK, Mathers BM, Cowie B, Hagan H, Jarlais DD, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 13 août. 2011;378(9791):571–83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285467</ArticleId><ArticleId IdType="pubmed">21802134</ArticleId></ArticleIdList></Reference><Reference><Citation>White B, Dore GJ, Lloyd A, Rawlinson W, Maher L. Ongoing susceptibility to hepatitis B virus infection among people who inject drugs in Sydney. Aust N Z J Public Health. 2012;36(4):351–6.</Citation></Reference><Reference><Citation>Burström B, Tao W. Social determinants of health and inequalities in COVID-19. Eur J Public Health 1 août. 2020;30(4):617–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454505</ArticleId><ArticleId IdType="pubmed">32638998</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry janv. 2021;26(1):30–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488216</ArticleId><ArticleId IdType="pubmed">32929211</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolopa C, Hoj S, Bruneau J, Meeson JS, Minoyan N, Raynault MF, et al. A rapid review of the impacts of big events on risks, harms, and service delivery among people who use drugs: implications for responding to COVID-19. Int J Drug Policy juin. 2021;92:103127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816610</ArticleId><ArticleId IdType="pubmed">33549464</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhoudian A, Radfar SR, Ardabili HM, Rafei P, Ebrahimi M, Zonoozi AK et al. A global survey on changes in the supply, price and use of illicit drugs and alcohol, and related complications during the 2020 COVID-19 pandemic. medRxiv. 24 juill 2020;2020.07.16.20155341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377291</ArticleId><ArticleId IdType="pubmed">34421664</ArticleId></ArticleIdList></Reference><Reference><Citation>Minoyan N, Høj SB, Zolopa C, Vlad D, Bruneau J, Larney S. Self-reported impacts of the COVID-19 pandemic among people who use drugs: a rapid assessment study in Montreal, Canada. Harm Reduct J déc. 2022;19(1):38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9013973</ArticleId><ArticleId IdType="pubmed">35436936</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasylyeva TI, Smyrnov P, Strathdee S, Friedman SR. Challenges posed by COVID-19 to people who inject drugs and lessons from other outbreaks. J Int AIDS Soc [Internet] 22 juill 2020 [cité 15 janv 2021];23(7). Disponible sur: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375066/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375066</ArticleId><ArticleId IdType="pubmed">32697423</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens G, Gerritsen L, Duijndam S, Salemink E, Engelhard IM. Fear of the coronavirus (COVID-19): predictors in an online study conducted in March 2020. J Anxiety Disord août. 2020;74:102258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286280</ArticleId><ArticleId IdType="pubmed">32569905</ArticleId></ArticleIdList></Reference><Reference><Citation>Health. rights and drugs — Harm reduction, decriminalization and zero discrimination for people who use drugs [Internet]. [cité 21 nov 2022]. Disponible sur: https://www.unaids.org/en/resources/documents/2019/JC2954_UNAIDS_drugs_report_2019</Citation></Reference><Reference><Citation>Taming of the Flu. Engagement, barriers and correlates of influenza vaccination uptake among people who inject drugs in Australia | NDARC - National Drug and Alcohol Research Centre [Internet]. [cité 21 sept 2022]. Disponible sur: https://ndarc.med.unsw.edu.au/resource/taming-flu-engagement-barriers-and-correlates-influenza-vaccination-uptake-among-people-who</Citation></Reference><Reference><Citation>Bertin P, Nera K, Delouvée S, Conspiracy Beliefs. Rejection of vaccination, and support for hydroxychloroquine: a conceptual replication-extension in the COVID-19 pandemic context. Front Psychol [Internet]. 2020. 10.3389/fpsyg.2020.565128. [cité 6 juin 2023];11. Disponible sur:. https://www.frontiersin.org/articles/.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7536556</ArticleId><ArticleId IdType="pubmed">33071892</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivas-de-Roca R, Pérez-Curiel C. Global political leaders during the COVID-19 vaccination: between propaganda and fact-checking. Polit Life Sci J Assoc Polit Life Sci Avr. 2023;42(1):104–19.</Citation><ArticleIdList><ArticleId IdType="pubmed">37140226</ArticleId></ArticleIdList></Reference><Reference><Citation>Parimi K, Gilkeson K, Creamer BA. COVID-19 vaccine hesitancy: considerations for reluctance and improving vaccine uptake. Hum Vaccines Immunother. nov 2022;30(5):2062972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9897654</ArticleId><ArticleId IdType="pubmed">35436173</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajos N, Spire A, Silberzan L, for the EPICOV study group. The social specificities of hostility toward vaccination against Covid-19 in France. Patel SKS, éditeur. PLOS ONE 6 janv. 2022;17(1):e0262192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8735622</ArticleId><ArticleId IdType="pubmed">34990482</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittet D, Boone L, Moulin AM, Briet R, Parneix P. Mission indépendante nationale sur l’évaluation de la gestion de la crise Covid-19 et sur l’anticipation des risques pandémiques - Rapport final [Internet]. 2021 mai [cité 6 mars 2023]. Disponible sur: http://www.vie-publique.fr/rapport/279851-gestion-crise-covid-et-anticipation-de-risques-pandemiques-rapport-final</Citation></Reference><Reference><Citation>Riegel L, Di Ciaccio M, Ben Moussa A, Velter A, Acosta ME, Villes V et al. La Recherche communautaire en temps de pandémie: retour sur l’étude multi-pays EPIC: Santé Publique. 23 mars 2022;Prépublication(0):i1–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">35724175</ArticleId></ArticleIdList></Reference><Reference><Citation>Delabre RM, Ciaccio MD, Lorente N, Villes V, Avila JC, Yattassaye A et al. Impact of the COVID-19 Health Crisis on Key Populations at Higher Risk for, or Living With, HIV or Hepatitis C Virus and People Working With These Populations: Multicountry Community-Based Research Study Protocol (EPIC Program). JMIR Res Protoc. 14 déc. 2023;12(1):e45204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10755648</ArticleId><ArticleId IdType="pubmed">38096016</ArticleId></ArticleIdList></Reference><Reference><Citation>Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 22 mai. 2006;166(10):1092–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16717171</ArticleId></ArticleIdList></Reference><Reference><Citation>Patient Health Questionnaire (PHQ-9.) – Strokengine [Internet]. [cité 31 août 2022]. Disponible sur: https://strokengine.ca/fr/assessments/patient-health-questionnaire-phq-9/</Citation></Reference><Reference><Citation>Ward JK, Bauer J. Attitudes of French adults toward COVID-19 vaccination. Infect Dis Now 12 sept 2022;S2666-9919(22)00189-0.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9467923</ArticleId><ArticleId IdType="pubmed">36108976</ArticleId></ArticleIdList></Reference><Reference><Citation>Dietze PM, Hall C, Price O, Stewart AC, Crawford S, Peacock A, et al. COVID-19 vaccine acceptability among people in Australia who inject drugs: implications for vaccine rollout. Drug Alcohol Rev févr. 2022;41(2):484–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653113</ArticleId><ArticleId IdType="pubmed">34752659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cioffi CC, Kosty D, Nachbar S, Capron CG, Mauricio AM, Tavalire HF. COVID-19 vaccine deliberation among people who inject drugs. Drug Alcohol Depend Rep Juin. 2022;3:100046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942572</ArticleId><ArticleId IdType="pubmed">35345466</ArticleId></ArticleIdList></Reference><Reference><Citation>Cepeda JA, Feder KA, Astemborski J, Schluth C, Kirk GD, Mehta SH et al. COVID-19 Vaccine Hesitancy and Vaccination Status in a Community-Based Cohort of People Who Inject Drugs in Baltimore, Maryland, March-June 2021. Public Health Rep Wash DC. 1974. oct 2022;137(5):1031–40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9357826</ArticleId><ArticleId IdType="pubmed">35848111</ArticleId></ArticleIdList></Reference><Reference><Citation>Strathdee SA, Abramovitz D, Harvey-Vera A, Vera CF, Rangel G, Artamonova I et al. Correlates of Coronavirus Disease 2019 (COVID-19) Vaccine Hesitancy Among People Who Inject Drugs in the San Diego-Tijuana Border Region. Clin Infect Dis Off Publ Infect Dis Soc Am. 24 août. 2022;75(1):e726–33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8690110</ArticleId><ArticleId IdType="pubmed">35024825</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasmin F, Najeeb H, Asghar MS, Ullah I, Islam SMS. Increased COVID-19 infection risk, COVID-19 vaccine inaccessibility, and unacceptability: worrisome trio for patients with substance abuse disorders. J Glob Health 2 oct. 2021;11:03106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8501395</ArticleId><ArticleId IdType="pubmed">34671459</ArticleId></ArticleIdList></Reference><Reference><Citation>Iversen J, Wand H, Kemp R, Bevan J, Briggs M, Patten K, et al. Uptake of COVID-19 vaccination among people who inject drugs. Harm Reduct J 3 juin. 2022;19(1):59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9162792</ArticleId><ArticleId IdType="pubmed">35655217</ArticleId></ArticleIdList></Reference><Reference><Citation>Strathdee SA, Abramovitz D, Vera CF, Artamonova I, Patterson TL, Smith DM, et al. Predictors of COVID-19 vaccine uptake among people who inject drugs. Vaccine 3 mars. 2023;41(12):1916.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9868393</ArticleId><ArticleId IdType="pubmed">36697311</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleaume C, Verger P, Dib F, Ward JK, Launay O, Peretti-Watel P. Intention to get vaccinated against COVID-19 among the general population in France: Associated factors and gender disparities. Hum Vaccines Immunother. oct 2021;3(10):3421–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437523</ArticleId><ArticleId IdType="pubmed">34292140</ArticleId></ArticleIdList></Reference><Reference><Citation>Price O, Dietze PM, Maher L, Crawford S, Peacock A. COVID-19 vaccine acceptability among people in Australia who inject drugs: update from the 2021 Illicit Drug Reporting System interviews. Drug Alcohol Rev Juill. 2022;41(5):1025–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9111623</ArticleId><ArticleId IdType="pubmed">35184346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellis AM, Kelly BC, Potenza MN, Hulsey JN. Trust in a COVID-19 vaccine among people with substance use disorders. Drug Alcohol Depend 1 mars. 2021;220:108519.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797771</ArticleId><ArticleId IdType="pubmed">33461150</ArticleId></ArticleIdList></Reference><Reference><Citation>Roederer T, Mollo B, Vincent C, Leduc G, Sayyad-Hilario J, Mosnier M et al. Estimating COVID-19 vaccine uptake and its drivers among migrants, homeless and precariously housed people in France. Commun Med. 20 févr. 2023;3(1):30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9939372</ArticleId><ArticleId IdType="pubmed">36801917</ArticleId></ArticleIdList></Reference><Reference><Citation>Barocas JA. Business Not as Usual — Covid-19 Vaccination in Persons with Substance Use Disorders. N Engl J Med. 14 janv. 2021;384(2):e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33378604</ArticleId></ArticleIdList></Reference><Reference><Citation>Advancing Drug Policy Reform, The Global Commission on Drug Policy. : a new approach to decriminalization [Internet]. 2016 [cité 8 juin 2023]. Disponible sur: https://www.globalcommissionondrugs.org/reports/advancing-drug-policy-reform</Citation></Reference><Reference><Citation>Strully KW, Harrison TM, Pardo TA, Carleo-Evangelist J. Strategies to address COVID-19 vaccine hesitancy and mitigate Health disparities in Minority populations. Front Public Health 23 avr. 2021;9:645268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8102721</ArticleId><ArticleId IdType="pubmed">33968884</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidari O, O’Conor KJ, Meyer D, Cargill V, Lowensen K, Farley JE. High primary COVID-19 Vaccine Series Completion by People Who Inject Drugs When Colocating Services at a Syringe Services Van. J Addict Med 1 oct. 2023;17(5):e287–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10492892</ArticleId><ArticleId IdType="pubmed">37788618</ArticleId></ArticleIdList></Reference><Reference><Citation>Darke S. Self-report among injecting drug users: a review. Drug Alcohol Depend 1 août. 1998;51(3):253–63. discussion 267–268.</Citation><ArticleIdList><ArticleId IdType="pubmed">9787998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>